98%
921
2 minutes
20
Vaccination hesitancy is an important barrier for the effective control of the COVID-19 pandemic. Identifying determinants of COVID-19 vaccination hesitancy is essential in order to reduce mortality rates. Further, given the variability of the factors and the different recommendations used in each country, it is important to conduct cross-country research to profile individuals who are hesitant toward COVID-19 vaccinations. This cross-sectional study aimed to examine cross-country differences and the behavioral, attitudinal and demographic characteristics of vaccine hesitant individuals. Adults living in six European countries (Cyprus, France, Germany, Italy, Poland, and Spain) were eligible to participate. A total of 832 individuals completed the online survey, with 17.9% reporting being hesitant to COVID-19 vaccination. Vaccine accepters were significantly older ( 38.9, 14.3), more educated (master/postgraduate studies) and lived in a place with a higher number of residents (>500,000 people) compared to those hesitant to COVID-19 vaccination. Discriminant analysis confirmed that the hesitant profile includes a person of younger age, living alone in smaller communities, and without children. Additionally, hesitant participants reported COVID-19-specific characteristics such as lower institutional trust, less adherence to COVID-19 protective behaviors and higher pandemic fatigue. When tackling COVID-19 vaccination hesitancy both socio-demographic and behavioral/attitudinal aspects should be taken into account. Stakeholders are advised to implement targeted vaccination programs while at the same time building trust with population illness cognitions addressed in order to reduce hesitancy rates. Further, stakeholders and public health authorities in each country are suggested to target interventions according to different population characteristics as behavioral and attitudinal determinants of COVID-19 vaccination hesitancy differed between countries.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/08964289.2022.2071198 | DOI Listing |
Virol Sin
September 2025
State Key Laboratory of Virology and Biosafety, RNA Institute, College of Life Sciences and Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, 430072, China; Institute for Vaccine Research at Animal Bio-safety Level Ⅲ Laboratory, Wuhan University, Wuhan, 430071, China.
Since the outbreak of SARS-CoV-2 in late 2019, the cumulative number of confirmed cases worldwide has surpassed 778 million, and the number of deaths has exceeded 7 million, posing a significant threat to human life and health while inflicting enormous losses on the global economy. At the stage where sequential immunization is recommended, there is a pressing demand for mRNA vaccines that can be rapidly adapted to new sequences, are easy to industrialize, and exhibit high safety and effectiveness. We developed a lipid nanoparticle (LNP) system, designated as WNP, which facilitates essentially in situ expression at the injection site and results in lower levels of pro-inflammatory factors in the liver, thus enhancing its safety compared to liver-targeted alternatives.
View Article and Find Full Text PDFVaccine
September 2025
Brighton Collaboration, The Task Force for Global Health, Atlanta, GA, United States of America.
Vaccine safety surveillance systems are vital for the post-market safety monitoring of novel and well-established vaccines, given the sample size, representativeness and follow-up time in clinical trials. The introduction of COVID-19 vaccines during the SARS-CoV-2 pandemic presented unprecedented challenges for safety surveillance. Here, we discuss methodologic considerations for epidemiologic study design and real world data for passive and active surveillance systems for COVID-19 vaccines in the United States (U.
View Article and Find Full Text PDFVaccine
September 2025
Department of Psychology, University of Miami, Coral Gables, FL, USA. Electronic address:
Existing inequities are exacerbated during the COVID-19 pandemic. Similar to HIV, COVID-19 disproportionately affects Black and other communities of color. Among Black women living with HIV (BWLWH) this study examined the relationship between community level and individual level social determinants of health and time to COVID-19 vaccine uptake.
View Article and Find Full Text PDFVaccine
September 2025
Department of Pharmacy, University of Rajshahi, Rajshahi 6205, Bangladesh.
Despite the therapeutic potential of the primary vaccine series, a lack of confidence in the COVID-19 booster vaccine poses a threat to public health and undermines its coverage at the national, regional, and global levels. This study aimed to understand COVID-19 booster vaccine confidence (CBVC) among Bangladeshi adults aged 18-49 and the potential predictors of CBVC. In line with STROBE guidelines, a face-to-face cross-sectional survey was conducted from June 15 to August 31, 2023 during the spread of the SARS-CoV-2 Omicron variant.
View Article and Find Full Text PDFAutoimmunity
December 2025
Medicinal Genomics, Beverly, MA, USA.
For some of the COVID-19 vaccines, the drug substances released to market were manufactured differently than those used in clinical trials. Manufacturing nucleoside-modified mRNA (modRNA) for commercial COVID-19 vaccines relies on RNA polymerase transcription of a plasmid DNA template. Previous studies identified high levels of plasmid DNA in vials of modRNA vaccines, suggesting that the removal of residual DNA template is problematic.
View Article and Find Full Text PDF